New hope for advanced cancers: first human trial of ERX-315 begins

NCT ID NCT06533332

First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 31 times

Summary

This early-stage study tests a new drug called ERX-315 in people with advanced solid tumors (like breast, ovarian, or pancreatic cancer) that no longer respond to standard treatments. The main goal is to check the drug's safety and find the best dose for future studies. About 15 participants will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Research SA

    RECRUITING

    Adelaide, South Australia, 5000, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Icon Cancer Centre Adelaide

    RECRUITING

    Adelaide, South Australia, 5037, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Macquarie University Health

    RECRUITING

    Ryde, New South Wales, 2109, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The Kinghorn Cancer Center

    RECRUITING

    Sydney, New South Wales, 2010, Australia

Conditions

Explore the condition pages connected to this study.